echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Qilu grabs microspheres, the first imitation Novartis billion-level injection, soars by 80%

    Qilu grabs microspheres, the first imitation Novartis billion-level injection, soars by 80%

    • Last Update: 2022-01-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      On January 7, Qilu submitted an application for 4 types of generic octreotide acetate microspheres for injection, which is expected to hit the first domestic imitation
    .
    The original research company of the microsphere preparation is Novartis.
    In 2020, the terminal sales in China's public medical institutions will exceed 400 million yuan.
    Changchun Jinsai Pharmaceutical and Livzon Group have been approved for clinical use

    .
     
      Figure 1: The latest products declared by Qilu
      Source: CDE official website
     
      Figure 2: Sales of octreotide acetate microspheres for injection (unit: ten thousand yuan)
      Source: Minet.
    com China's public medical institutions terminal competition pattern
     
    Octreotide acetate microspheres for injection are long-acting injections of octreotide, which only need to be administered once a month, and are the first choice for   the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors
    .
    Novartis' original research drug entered the Chinese market in 2003, and there are no generic drugs listed in China.
    According to Minet.
    com data, in 2020, there will be public hospitals in China
    , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
    ) terminal, the sales of original research drugs have exceeded 400 million yuan, and the growth rate in 2020 is still as high as 88% under the influence of the epidemic, and the market potential should not be underestimated

    .
     
      Figure 3: Clinical progress related to octreotide acetate microspheres for injection
      Source: Minet China Drug Clinical Trials Publicity Library
     
      Changchun Jinsai Pharmaceutical obtained clinical approval in 2017, and Phase I clinical trials are currently underway; Livzon Group will report production in 2020, and then obtain clinical approval; Qilu completed BE in 2021, and is now applying for listing, depending on the progress Look, winning the first copy is a high probability event
    .
     
      In recent years, Qilu has made great efforts in the field of new formulations, and has gradually built a research and development and production platform for new formulations such as microspheres, nanoparticles, oral dissolving films, and soft capsules, and realized the industrialization of many scientific research results
    .
     
      Taking the oral dissolving pipeline as an example, Qilu has obtained the production approvals for olanzapine oral dissolving film, montelukast sodium oral dissolving film, aripiprazole oral dissolving film, tadalafil oral dissolving film, and methicillin hydrochloride.
    The King Kong oral dissolving film is being reported for production.
    In addition, the clinical approvals for escitalopram oxalate oral dissolving film, risperidone oral dissolving film and vardenafil hydrochloride oral dissolving film are also in its capsule

    .
    The application for listing of octreotide acetate microspheres for injection is a solid step taken by the company in the microsphere preparation pipeline

    .
     
      Source: Minet database, CDE official website
     
      The statistics of clinical data are as of January 6.
    If there are any mistakes or omissions, please correct me

    .
      On January 7, Qilu submitted an application for 4 types of generic octreotide acetate microspheres for injection, which is expected to hit the first domestic imitation
    .
    The original research company of the microsphere preparation is Novartis.
    In 2020, the terminal sales in China's public medical institutions will exceed 400 million yuan.
    Changchun Jinsai Pharmaceutical and Livzon Group have been approved for clinical use

    .
     
      Figure 1: The latest products declared by Qilu
      Source: CDE official website
     
      Figure 2: Sales of octreotide acetate microspheres for injection (unit: ten thousand yuan)
      Source: Minet.
    com China's public medical institutions terminal competition pattern
     
    Octreotide acetate microspheres for injection are long-acting injections of octreotide, which only need to be administered once a month, and are the first choice for   the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors
    .
    Novartis' original research drug entered the Chinese market in 2003, and there are no generic drugs listed in China.
    According to Minet.
    com data, in 2020, there will be public hospitals in China
    , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
    ) terminal, the sales of original research drugs have exceeded 400 million yuan, and the growth rate in 2020 is still as high as 88% under the influence of the epidemic, and the market potential should not be underestimated

    .
     
      Figure 3: Clinical progress related to octreotide acetate microspheres for injection
      Source: Minet China Drug Clinical Trials Publicity Library
     
      Changchun Jinsai Pharmaceutical obtained clinical approval in 2017, and Phase I clinical trials are currently underway; Livzon Group will report production in 2020, and then obtain clinical approval; Qilu completed BE in 2021, and is now applying for listing, depending on the progress Look, winning the first copy is a high probability event
    .
     
      In recent years, Qilu has made great efforts in the field of new formulations, and has gradually built a research and development and production platform for new formulations such as microspheres, nanoparticles, oral dissolving films, and soft capsules, and realized the industrialization of many scientific research results
    .
     
      Taking the oral dissolving pipeline as an example, Qilu has obtained the production approvals for olanzapine oral dissolving film, montelukast sodium oral dissolving film, aripiprazole oral dissolving film, tadalafil oral dissolving film, and methicillin hydrochloride.
    The King Kong oral dissolving film is being reported for production.
    In addition, the clinical approvals for escitalopram oxalate oral dissolving film, risperidone oral dissolving film and vardenafil hydrochloride oral dissolving film are also in its capsule

    .
    The application for listing of octreotide acetate microspheres for injection is a solid step taken by the company in the microsphere preparation pipeline

    .
     
      Source: Minet database, CDE official website
     
      The statistics of clinical data are as of January 6.
    If there are any mistakes or omissions, please correct me

    .
      On January 7, Qilu submitted an application for 4 types of generic octreotide acetate microspheres for injection, which is expected to hit the first domestic imitation
    .
    The original research company of the microsphere preparation is Novartis.
    In 2020, the terminal sales in China's public medical institutions will exceed 400 million yuan.
    Changchun Jinsai Pharmaceutical and Livzon Group have been approved for clinical use

    .
     
      Figure 1: The latest products declared by Qilu
      Source: CDE official website
     
      Figure 2: Sales of octreotide acetate microspheres for injection (unit: ten thousand yuan)
      Source: Minet.
    com China's public medical institutions terminal competition pattern
     
    Octreotide acetate microspheres for injection are long-acting injections of octreotide, which only need to be administered once a month, and are the first choice for   the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors
    .
    Novartis' original research drug entered the Chinese market in 2003, and there are no generic drugs listed in China.
    According to Minet.
    com data, in 2020, there will be public hospitals in China
    , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions).
    ) terminal, the sales of original research drugs have exceeded 400 million yuan, and the growth rate in 2020 is still as high as 88% under the influence of the epidemic, and the market potential should not be underestimated

    .
    Cancer Cancer Hospital Hospital Hospital_
     
      Figure 3: Clinical progress related to octreotide acetate microspheres for injection
      Source: Minet China Drug Clinical Trials Publicity Library
     
      Changchun Jinsai Pharmaceutical obtained clinical approval in 2017, and Phase I clinical trials are currently underway; Livzon Group will report production in 2020, and then obtain clinical approval; Qilu completed BE in 2021, and is now applying for listing, depending on the progress Look, winning the first copy is a high probability event
    .
     
      In recent years, Qilu has made great efforts in the field of new formulations, and has gradually built a research and development and production platform for new formulations such as microspheres, nanoparticles, oral dissolving films, and soft capsules, and realized the industrialization of many scientific research results
    .
     
      Taking the oral dissolving pipeline as an example, Qilu has obtained the production approvals for olanzapine oral dissolving film, montelukast sodium oral dissolving film, aripiprazole oral dissolving film, tadalafil oral dissolving film, and methicillin hydrochloride.
    The King Kong oral dissolving film is being reported for production.
    In addition, the clinical approvals for escitalopram oxalate oral dissolving film, risperidone oral dissolving film and vardenafil hydrochloride oral dissolving film are also in its capsule

    .
    The application for listing of octreotide acetate microspheres for injection is a solid step taken by the company in the microsphere preparation pipeline

    .
     
      Source: Minet database, CDE official website
     
      The statistics of clinical data are as of January 6.
    If there are any mistakes or omissions, please correct me

    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.